The final week in July is always a busy time in the English Courts as Judges try to hand down judgments before the commencement of the summer vacation which lasts approximately two months. 2013 was no exception with three important patent decisions being given this week– two from the Court of Appeal on the same…
It could be argued that 2013 is proving to be somewhat unkind to UK patentees when it comes to the issues of sufficiency and priority. On 25 June 2013, in a typically comprehensive judgment running to some 90 pages, Arnold J held that Janssen’s patent was invalid for insufficiency. The relevant facts were as follows:…
Judgments from the English Courts are nowadays usually delivered in draft form and in strictest confidence from the Judge’s clerk to the parties by way of an attachment to an email. This invariably causes an anxious lawyer to open the document and to hit “Ctrl/End” to find the conclusion of the Court, followed by a…
Today the UPC Rules Committee is passing the official version of the 15th draft of the UPC Rules of Procedure to the Commission. It is anticipated that this will become the first draft for official release very soon by the Preparatory Committee, and then be the subject of a period (probably three months) of public…
On 21 May 2013, the Court of Appeal issued its rejection of Lilly’s appeal in relation to Actavis’ purported service of an application for a Declaration of Non Infringement (DNI) in respect of not only the UK designation of Lilly’s European Patent relating to a particular salt form of pemetrexed (“the Patent”), but also the…
In its decision of 22 April*, the UK High Court (Mr Justice Arnold) has dismissed Nestec’s** claims that Dualit has infringed EP (UK) 2 103 236 (“the patent”) by supplying its own branded “NX Café Caps” coffee capsules which are compatible with Nestec’s Nespresso coffee machines, thus paving the way for new entrants into the…
On 12 April 2013, Mr Justice Arnold gave judgment in the English High Court in Resolution Chemicals Limited v H Lundbeck A/S ([2013] EWHC 739 (Pat)). Resolution (a generic supplier company) sought revocation of Lundbeck’s SPC/GB02/049 (the “SPC”) for escitalopram, alleging invalidity of the basic patent EP (UK) 0 347 066 (“the 066 patent”). Although…
In our post on 30 October 2012 we referred to forthcoming appeals dealing with how the question of obviousness should be tackled by the English courts. The Court of Appeal has now given its verdict in several judgments. The latest decision in Regeneron v Genentech dealt not only with the question of obviousness but also…
As previously reported on this blog, the new Unified Patent Court (UPC) will bring the biggest change in the patent litigation landscape Europe has ever seen. It will soon be possible to obtain a single court decision effective across the whole of a market worth around €10 trillion. The UPC will have jurisdiction over not…
As has been well publicised, the end of 2012 was a time of considerable progress in the long history of the Unitary patent and Unified Patent Court (“UPC”) dossier, culminating in adoption of the Unitary Patent Regulation 1257/2012 and its accompanying Language Regulation 1260/2012. But what next? Built into the Unitary Patent Regulation is a…
